Evidence map›Paper›PMID 24850846›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2014

Ectopic expression of cancer-testis antigens in cutaneous T-cell lymphoma patients.

Ivan V Litvinov, Brendan Cordeiro, Yuanshen Huang, Hanieh Zargham, Kevin Pehr, Marc-André Doré, Martin Gilbert, Youwen Zhou, Thomas S Kupper, Denis Sasseville

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Ectopic expression of meiotic cohesin generates chromosome instability in cancer cell line.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Ivan V LitvinovAuthors' Affiliations: Division of Dermatology, McGill University Health Centre, Montréal; denis.sasseville@mcgill.ca ivan.litvinov@mail.mcgill.ca.
Brendan CordeiroAuthors' Affiliations: Division of Dermatology, McGill University Health Centre, Montréal;
Yuanshen HuangDepartment of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada; and.
Hanieh ZarghamAuthors' Affiliations: Division of Dermatology, McGill University Health Centre, Montréal;
Kevin PehrAuthors' Affiliations: Division of Dermatology, McGill University Health Centre, Montréal;
Marc-André DoréDivision of Dermatology, Université Laval, Québec;
Martin GilbertDivision of Dermatology, Université Laval, Québec;
Youwen ZhouDepartment of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada; and.
Thomas S KupperHarvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard University, Boston, Massachusetts.
Denis SassevilleAuthors' Affiliations: Division of Dermatology, McGill University Health Centre, Montréal; denis.sasseville@mcgill.ca ivan.litvinov@mail.mcgill.ca.
McGill University Health Centre · CAUniversité Laval · CAUniversity of British Columbia · CAHarvard University · US

Funding

Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities forP50CA093683 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GOLUB, TODD R. · 2001 to 2012
$25.8M
NCI NIH HHS P50 CA093683
6 · The paper itself

Abstract

purposeThe pathogenesis of cutaneous T-cell lymphoma (CTCL) remains only partially understood. A number of recent studies attempted to identify novel diagnostic markers and future therapeutic targets. One group of antigens, cancer-testis (CT) antigens, normally present solely in testicular germ cells, can be ectopically expressed in a variety of cancers. Currently, only a few studies attempted to investigate the expression of CT antigens in CTCL. EXPERIMENTAL

designIn the present work, we test the expression of CT genes in a cohort of patients with CTCL, normal skin samples, skin from benign inflammatory dermatoses, and in patient-derived CTCL cells. We correlate such expression with the p53 status and explore molecular mechanisms behind their ectopic expression in these cells.

resultsOur findings demonstrate that SYCP1, SYCP3, REC8, SPO11, and GTSF1 genes are heterogeneously expressed in patients with CTCL and patient-derived cell lines, whereas cTAGE1 (cutaneous T-cell lymphoma-associated antigen 1) was found to be robustly expressed in both. Mutated p53 status did not appear to be a requirement for the ectopic expression of CT antigens. While T-cell stimulation resulted in a significant upregulation of STAT3 and JUNB expression, it did not significantly alter the expression of CT antigens. Treatment of CTCL cells in vitro with vorinostat or romidepsin histone deacetylase inhibitors resulted in a significant dose-dependent upregulation of mRNA but not protein. Further expression analysis demonstrated that SYCP1, cTAGE1, and GTSF1 were expressed in CTCL, but not in normal skin or benign inflammatory dermatoses.

conclusionsA number of CT genes are ectopically expressed in patients with CTCL and can be used as biomarkers or novel targets for immunotherapy.

Indexed as

Antigens, Differentiation, T-LymphocyteAntigens, NeoplasmBiomarkers, TumorCell Line, TumorDNA-Binding ProteinsGene ExpressionHistone Deacetylase InhibitorsHumansIntracellular Signaling Peptides and ProteinsLymphoma, T-Cell, CutaneousMembrane GlycoproteinsMutationNuclear ProteinsProteinsSkin NeoplasmsTumor Suppressor Protein p53Antigens, Differentiation, T-LymphocyteAntigens, NeoplasmBiomarkers, TumorCTAGE1 protein, humanDNA-Binding ProteinsGTSF1 protein, humanHistone Deacetylase InhibitorsIntracellular Signaling Peptides and ProteinsMembrane GlycoproteinsNuclear ProteinsProteinsSYCP1 protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID24850846
PMCPMC4863442
OpenAlexW1985964388

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.